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Hypertension in pregnancy is associated with increased maternal and fetal mortality 
and morbidity. About 8 % of all pregnancies are complicated with hypertensive disorders. 
There is  concordance that severe hypertension should be treated without delay to reduce 
maternal risks of acute cerebrovascular complications. Intravenous labetalol and oral 
nifedipine are as effective as intravenous hydralazine in control of severe hypertension, 
with less adverse effects. Still, there is no consensus as to whether mild-to-moderate 
hypertension in pregnancy should be treated, considering that there are no definitive 
conclusions which can be made about the relative maternal or perinatal benefits/risks of 
antihypertensive treatment. Considering their safe usage during pregnancy, methyldopa, 
labetalol and nifedipine are commonly used blood-pressure lowering drugs for pregnant 
women with hypertension. The cardio-selective β- blocker atenolol should be avoided in 
pregnancy, because it has been associated with lower birth weights and fetal growth 
impairment. ACE inhibitors and angiotensin receptor blockers are contraindicated in 
pregnancy. Acta Medica Medianae 2008;47(3):65-72. 
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Hypertensive pregnancy disorders - 
definitions and classification  
 
Hypertensive disorders are among the most 
common of all medical complications in pregnancy 
and are the leading cause of maternal and perinatal 
morbidity and mortality (1). Approximately, 8% 
of all pregnancies are complicated by hypertension 
(2). It was estimated that 192 women die every 
day because of complications of pregnancy 
hypertension (3). 
Hypertension in pregnancy is defined by 
systolic blood pressure (sBP)≥140 mmHg and/or 
diastolic blood pressure (dBP)≥90 mmHg, or by 
increase in sBP≥30 mmHg, or in dBP≥15 mmHg, 
from preconception or first trimester blood pressure 
confirmed by two measuring, 6 hours apart.  
There are four major hypertensive disorders 
in pregnancy, each with specific characteristics. 
In chronic hypertension, blood pressure (BP) is 
diagnosed before pregnancy in the first 20 weeks 
of gestation, or persists 42 days after delivery 
≥140/90 mmHg. In transient (now gestational) 
hypertension blood pressure ≥140/90 mmHg was 
established after the 20th week of gestation, and 
is not associated with proteinuria. 
 
Preeclampsia-eclampsia 
 
Preeclampsia is generally regarded as very 
important complication of pregnancy which is 
more dangerous than gestational or chronic 
hypertension, and is characterised by 
hypertension, proteinuria (≥0.3 g/24 hours) and 
oedema after the 20
th week of gestation. 
Eclampsia is described as the appearance of 
generalised convulsion(s) associated with the 
signs of preeclampsia, or their occurrance within 
7 days of parturition, and not caused by epilepsy 
or other convulsive disorders. Preeclampsia 
superimposed on chronic hypertension is defined 
as a condition of hypertension (BP≥140/90 
mmHg) with onset of proteinuria (4,5). 
In compliance with the decision of the 
National High Blood Pressure Education Program 
Working Group on High Blood Pressure in 
Pregnancy, the transient hypertension was renamed 
into gestational hypertension, and presents the 
condition of increased blood pressure during 
pregnancy with the absence of preeclampsia at 
the time of delivery and normalisation of BP 
during the following 12 weeks after delivery. 
Also, in the definition of preeclampsia, oedema 
has been removed as a diagnostic criterion, thus 
the preeclampsia includes hypertension and 
proteinuria (6,7). 
Australasian Society for the Study of 
Hypertension in Pregnancy (ASSHP) also presented 
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in pregnancy (8). In the ASSHP system, 
gestational hypertension is hypertension after the 
20
th week of gestation. Women with preelampsia, 
in addition to hypertension have one or more of 
several abnormalities like proteinuria, elevated 
liver enzymes,  thrombocytopenia, or elevated 
values of uric acid, or neurological disease. 
  
  Dilemma related to the beginning of 
antihypertensive therapy 
 
While severe hypertension (sBP≥170 mmHg 
and/or dBP≥110 mmHg) in pregnancy represents 
a very serious risk for maternal health (9), mild-
to-moderate hypertension (BP from 140/90 to 
169/109 mmHg) in pregnancy is associated with 
lower maternal risk. 
The necessity for antihypertensive therapy 
and the selection of certain antihypertensive 
agents during pregnancy should be estimated 
upon of the relative risks and/or benefits for the 
individual pregnant women. Still, there is 
dilemma in clinical practice when to use 
antihypertensive medications or what level of BP 
to target during pregnancy. 
There is no suspicion about usage of 
antihypertensive drugs in cases of severe 
hypertension. BP≥170/110 mmHg corresponds to 
the level standing for a high risk of cerebrovas-
cular incident, because of which  the majority of 
obstetricians regard antihypertensive treatment 
as crucial for the mother (9). Identification of this 
specific risk made the control of acutely raised 
blood pressure as central point for women with 
severe hypertension, particularly that of 
preeclampsia (10). Coagulation disorders associated 
with severe preeclampsia represent additional 
complications and also require adequate therapy 
(11,12,13). 
In mild-to-moderate hypertension in pregnancy 
(BP from 140/90 to 169/109 mmHg), usage of 
antihypertensive drugs is still controversial. In 
those cases, when the situation is less certain, 
selection of patients, choice of drug and duration 
of pregnancy at the beginning of treatment may 
be of great importance. Sibai consider that women 
with mild, uncomplicated chronic hypertension 
will accomplish good perinatal outcome regardless 
of the use of antihypertensive therapy (14). 
Some consider there are little indications for drug 
treatment of mild-to-moderate hypertension 
(15). Withholding from the treatment of 
hypertension in pregnancy to the value of 100 
mmHg is not associated with additional maternal 
or fetal risk (16).  
Benefits and risks of antihypertensive 
treatment for mild-to-moderate hypertension are 
not completely defined in recent reviews, 
including a Cochrane meta-analysis (17,18). It 
appears that with the use of antihypertensive 
treatment, there is less risk of developing severe 
hypertension, but no difference in outcomes of 
preeclampsia, neonatal death, preterm birth, and 
small-for-gestational-age (SGA) infants. Some 
investigators concluded that women with mild 
hypertension do not need antihypertensive 
treatment if they are closely followed up during 
pregnancy and delivery, especially pregnant women 
without hypertension and proteinuria development 
before pregnancy (19). 
Doubts concerning antihypertensive drugs 
use in pregnancy mostly refer to the effects they 
might have on the developing fetus. Generally, 
antihypertensive agents cross the placental 
barrier and are present in various concentrations 
in the fetal circulation. It was noticed that the 
incidence of SGA infants and reduction of birth 
weight were increased with higher antihyper-
tensive-induced fall in mean arterial BP among 
women who took antihypertensives when BP 
reached 160/100 mmHg. Among women whose 
BP was normalized (dBP<90 mmHg), there was a 
decrease in the risk of severe hypertension, 
maternal hospitalization and "proteinuria at 
delivery", on the basis of which no definitive 
conclusions can be drawn about the relative 
maternal or fetal benefits/risks of antihypertensive 
treatment for mild-to-moderate pregnancy 
hypertension (20). 
International societies have differed in their 
attitudes and recommendations for the BP  which 
should initiate antihypertensive therapy. The U.S. 
professional bodies recommend starting with the 
therapy at BP≥160/105 mmHg, not defining the 
target values (6). The Canadian Hypertension 
Society recommends normalization of BP for 
most hypertensive pregnancy disorders with BP 
of 140-150/90-95 mmHg, targeting dBP of 80-89 
mmHg (21). The Australasian professional bodies 
recommend initiation of antihypertensive therapy 
at BP≥160/90 mmHg and conducting the therapy 
to the BP  value of 110-140/80-90 mmHg (8). It 
should be underlined that there are still no 
definitive and complete data about safe BP 
treatment targets for women with hypertension 
in pregnancy, however, guidelines and reviews 
generally recommend the introduction of 
antihypertensive treatment with the BP values of 
140 - 155/90 -105 mmHg (22). 
  
A wide choice of antihypertensive 
agents 
 
In accordance with intensive development 
of pharmaceutical industry in few last decades, 
the appearance of several different medical forms 
of the same medical substances is not unusual on 
market. Different medical forms can be 
considered as alternatives, pursuant to the scope 
of indications only if they are therapeutically 
equivalent, or, in other words, the same two 
preparations from different pharmaceutical 
producers must give the same clinical outcome. 
Besides, in our market, there are many generic 
drug forms used in hypertension therapy. It is 
very important that their efficiency and safety are 
the same as of brand-name drugs, because of 
why consequent bioequivalence testing may be of 
great significance (23). 
A wide spectrum of antihypertensive agents 
represents the key of successful pregnancy 
hypertension treatment and opportunity of choice, 
in accordance with indications and availability of 
drugs provided by drug tendering (24). Acta Medica Medianae 2008,Vol.47                                      Antihypertensive drug therapy for hypertensive disorders in pregnancy 
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Centrally acting α2-adrenergic 
agonists  
 
Methyldopa is the most frequently prescribed 
and the agent of first choice for treatment of 
hypertension in pregnancy (21), in accordance 
with the fact that there are extensive clinical 
experience with the drug and long-term follow-up 
data regarding children whose mothers received 
methyldopa during pregnancy with proven 
maternal and fetal safety (25,26). During the 
long- term utilization in chronic hypertension in 
pregnancy, methyldopa does not alter cardiac 
output or blood flow to the uterus or kidneys (9). 
This drug is also used to control hypertension in 
preeclampsia (27). Compared with the 
pretreatment values, the mean arterial blood 
pressure decreased significantly while, analysed 
by computed cardiotocography, fetal heart rate 
patterns were not significantly changed during 
the treatment with methyldopa (28). Based on 
the long history of use, methyldopa does not 
seem to be teratogenic (29). Mutch et al. 
reported that there are no significant differences 
between birth weight, neonatal complications and 
development during the first year in children 
exposed to methyldopa and placebo group (30). 
Except basic adverse effects which are directly 
related to its mechanism of action (fatigue, 
depression, poor sleep), elevated transaminases 
and a positive Coomb's test (which is occasionally 
associated with haemolytic anemia) are also 
annunciated (31).   
 
Peripherally acting adrenergic-
receptor antagonists 
 
Labetalol blocks both α- and β-adrenoceptors 
and produces its hypotensive effects without 
compromising the maternal cardiovascular 
system, which is significant in maintaining of 
renal and uterine blood flow. The results from 
multicentre, randomised, double-blind study in 
152 patients (20 to 38 weeks of gestation) with 
mild-to-moderate non-proteinuric hypertension 
demonstrated that labetalol, compared with 
placebo group, significantly reduces maternal 
blood pressure (p<0.001) without increase in 
intrauterine growth retardation and neonatal 
hypoglycaemia (32). In a trial which has included 
263 women with mild-to-moderate hypertension 
at 6 to 13 weeks of gestation, patients were 
randomly separated in three groups: first group 
(87 pregnant women) received methyldopa, 
second, labetalol (86 pregnant women) and 
group with no treatmant (90 pregnant women). 
The results showed that patients with therapy 
had significantly lower maternal blood pressures 
(p<0.0001) compared to the nonmedication 
group and that there were no differences among 
the groups concerning gestational age at 
delivery, birth weight, incidence of fetal growth 
retardation, neonatal head circumference or 
uteroplacental circulation (33). Redman also 
considers that uteroplacental circulation is not 
affected by labetalol (34). In preeclamptic 
hypertension treatment, labetalol can be deemed 
as safe and effective medicament (35). Parenterally, 
it is used to treat severe hypertension. Clinical 
studies of acute severe hypertension in pregnancy 
exhibited that labetalol was connected with less 
maternal hypotension than hydralazine (36). 
Adverse effects may be predicted on behalf of β-
receptor blockade. Although fatigue, lethargy, 
exercise intolerance, peripheral vasoconstriction, 
sleep disturbance and bronchoconstriction may 
appear, discontinuation of usage because of adverse 
effects is uncommon (17). 
Although atenolol is commonly used 
cardioselective β blocker in non-pregnancy, it has 
been considered that in pregnancy, especially in 
early pregnancy, usage of atenolol should be 
avoided. Based upon results of placebo-controlled 
study, which have been showed that in women 
with chronic hypertension, atenolol usage in early 
pregnancy (mean 15.9 weeks of pregnancy) is 
associated with the significantly lower birth 
weight (2620 vs 3530 g) and significantly higher 
proportion of small-for-gestational-age infants 
compared to the placebo group, the investigators 
concluded that atenolol had an adverse effect on 
birth weight and fetal growth (37). Lip et al. (38) 
reported significantly lower weight of babies born 
to women taking atenolol (p < 0.001) compared 
to those taking other β-blockers, other 
antihypertensives, or no therapy during the first 
20 weeks of pregnancy. Bayliss et al. expounded 
that low birth weight was associated with atenolol 
taken at the time of conception or during the first 
trimester of pregnancy (39). Lydakis et al. 
noticed and compared the differences between 
the mean birthweight at delivery depending on 
time when atenolol was given (40). When 
atenolol was given before the 20th week of 
gestation for a mean period of 23 to 26 weeks, 
the mean birthweight at delivery was 2010 g; 
when given between the 20th and 30th weeks of 
gestation for 12 weeks, it was 2402 g, and 2644 
g when given at > 30 weeks of gestation for 3 to 
5 weeks. In contrast to the adverse effects of 
reduced birthweight and SGA babies of early 
atenolol use in some trials, the study with 
atenolol in pregnancy-induced hypertension (41) 
failed to present any difference in average 
birthweight in mothers receiving β-blockers. This 
may be the result of the late starting with 
antihypertensive therapy. Atenolol should be 
avoided in early stages of pregnancy and given 
with caution at later stages, as it has been 
associated with fetal growth impairment and 
lower birth weights. 
Generally, oral beta-blockers for mild-to-
moderate hypertension during pregnancy have 
specifically been estimated in the Cochrane 
database (42). Oral beta-blockers (except atenonol) 
decrease the risk of severe hypertension. It has 
been estimated that beta-blockers appear to be 
associated with an increase in small-for-
gestational-age infants and frequency of neonatal 
bradycardia. Also, the respiratory distress 
syndrome and maternal hospital admissions 
decrease. Beta-blockers treatment seems to be 
no more effective compared with methyldopa.  Antihypertensive drug therapy for hypertensive disorders in pregnancy                                                   Marko Folić et al. 
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For severe hypertension, β blockers may be 
administered parenterally. As we have noted, 
intravenous labetalol has been, because of a 
lower incidence of maternal hypotension and 
other adverse effects, supplanted the usage of 
hydralazine, which was previously the most 
commonly used agent for the treatment of severe 
hypertension (36). 
 
Calcium Channel Antagonists  
 
Calcium antagonists produce direct arterial 
vasodilatation, by inhibiting entry of Ca
2+ in 
smooth muscle. These agents have been used in 
pregnancy, because they do not appear to 
produce a major teratogenic risk. Sibai et al. (43) 
studied 200 preeclamptic patients at 26 to 36 
weeks of gestation which were assigned 
randomly to treatment with bed rest alone or oral 
nifedipine plus bed rest. Blood pressures was 
significantly lower (p<0.0001) in patients who 
received nifedipine while severe hypertension 
was significantly more frequent (p<0.05) in the 
patient group with bed rest alone. The difference 
between the groups in regard to birthweight, 
incidence of small-for-gestational-age babies, 
preterm birth and the number of days spent in 
the special care unit was not detected. Nifedipine 
reduces maternal BP, however, in regard to the  
perinatal outcome or reduction in the number of 
days of maternal hospitalisation, this drug is not 
effective. Fenakel et al. (44) reported, based on 
the results of randomised clinical trial in which 
patients with severe preeclampsia between the 
26th and 36th weeks of gestation received either 
nifedipine or hydralazine, the effective control of 
blood pressure was attained with nifedipine in 
95.8% of patients and 68% of patients with 
hydralazine. Also, the average number of days 
spent in the neonatal intensive care unit was 
significantly lower in patients treated with 
nifedipine (15.1 vs 32.7 days; p<0.005). Magee 
et al. concluded that, in accordance with the 
results of a multicenter, cohort study which 
investigated the safety of calcium channel 
blockers in human pregnancy, nifedipine and 
verapamil, which have been best studied, did not 
seem to pose teratogenic risks to fetuses 
exposed in the first trimester (45).  
Brown et al. compared efficacy and safety 
of 10 mg nifedipine tablets with rapid onset and 
short-acting 10 mg nifedipine capsules for the 
treatment of severe hypertension in the second 
half of pregnancy (46). There was a smaller 
number of hypotensive episodes in women who 
took tablets. Fetal distress was rare with capsules 
and tablets. Authors concluded that, although 
slower at the start, nifedipine tablets were as 
effective as capsules for the rapid treatment of 
severe hypertension. Some other studies 
reported that administration of short-acting 
nifedipine capsules has been associated with 
maternal hypotension and fetal distress (47,48), 
which suggested the usage of a long-acting 
preparation.  
In addition, administration of MgSO4 to pre-
gnant women receiving calcium channel antagonists 
may result in severe hypotension (49) and 
neuromuscular blockade (50), so that the 
combination should be used carefully. 
 
Direct vasodilators 
 
Oral hydralazine has been widely used for 
chronic hypertension in the second and third 
trimesters, but its use has been supplanted by 
agents with more favorable adverse effects (51). 
Generally, hydralazine has been used in all 
trimesters of pregnancy and experiences with its 
usage have not shown an association with 
teratogenicity, although Widerlov et al. (52) 
reported neonatal thrombocytopenia and Yemini 
et al. (53) a case of maternal, and possibly 
neonatal, lupus after six days of parenteral 
hydralazine therapy for severe hypertension. 
Parenteral hydralazine was earlier considered to 
be the drug of choice for the treatment of acute 
severe hypertension in pregnancy, but a recent 
meta-analysis of intravenous hydralazine usage 
in severe hypertension in pregnancy concluded 
that parenteral labetalol or oral nifedipine were 
preferable first-line agents in accordance with 
association of intravenous hydralazine with more 
maternal and perinatal adverse effects than 
intravenous labetalol or oral nifedipine, such as 
maternal hypotension, maternal oliguria, 
caesarean sections, placental abruption, adverse 
effects on fetal heart rate and low Apgar scores 
at one minute (36). 
Sodium nitroprusside is potent, rapid-
acting and short-lasting drug which is used in 
pregnancy for the treatment of an acute 
hypertensive crisis not responding to other 
agents. Considering that utilization of this 
medicament may cause fetus cyanide poisoning, 
transient fetal bradycardia, metabolic acidosis, 
and maternal hypotension (54,55), it must be 
given under continuous surveillance and with 
caution. Also, it is recommended that when 
control of acute crisis is attained, the fetus 
should be delivered as soon as possible. 
Nitroprusside is a drug of last choice for the 
treatment of acute hypertension in pregnancy. 
 
Diuretics 
 
Diuretics are commonly orally administered 
antihypertensives in non-pregnant patients 
because of low cost and suitable impact on major 
cardiovascular events as shown in randomized 
controlled trials (56). Also, it has been claimed 
that diuretics prevent pre-eclampsia (57,58). 
Although diuretics reducing maternal plasma 
volume have been reported to be connected with 
poor perinatal outcome (59), negative affect on 
fetal growth has not been completely proven 
(60). Collins et al. concluded that there is no 
increment in neonatal thrombocytopenia or other 
adverse effects among diuretic-exposed 
newborns (61). Hydrochlorothiazide, triamterene Acta Medica Medianae 2008,Vol.47                                      Antihypertensive drug therapy for hypertensive disorders in pregnancy 
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and amiloride are not considered teratogenic 
(62). The usage of spironolactone is not advised 
because of its antiandrogenic effects during fetal 
development (63). Even though it was proven 
that the adverse effects of diuretics such as 
hypokalaemia or impaired glucose tolerance (64) 
can be minimized by using low doses, diuretics 
are not used frequently in pregnancy.  
 
Angiotensin-Converting-Enzyme 
Inhibitors and Angiotensin Receptor  
 
Antagonists 
Angiotensin-converting–enzyme (ACE) 
inhibitors are widely prescribed and well tolerated 
antihypertensives, but it is proved that their 
usage in the second and third trimesters of 
pregnancy may cause oligohydramnios, fetal growth 
retardation, pulmonary hypoplasia, joint contractures 
and neonatal renal failure, hypotension, and 
death (65,66,67). A similar fetal anomalies have 
been reported after treatment of women in the 
second or third trimester of pregnancy with 
angiotensin II receptor antagonists (68). 
Some studies have not reported fetopathy 
among women who took ACE inhibitors only 
during the first trimester of pregnancy. Lip et al. 
(69) reported no congenital abnormalities with 
any evident neonatal renal dysfunction in six 
women receiving ACE inhibitors in early 
pregnancy as a continuation of therapy for more 
than 12 weeks, including one who continued 
treatment until 25 weeks. Steffensen et al. (70) 
reported the outcome of 21 pregnant women who 
received ACE inhibitors during their first trimester 
(at 5 to 15 gestational weeks) between 1991 and 
1996. There were no stillborn babies. There was 
a case of one pre-term infant delivered at the 
27th  gestation week and died at 1 week of age, 
but with no signs of neonatal renal failure and no 
congenital malformation on performed autopsy. A 
case of congestive cardiomyopathy without 
structural malformation was also reported. 
Except these two cases, there were no other 
reports of any congenital abnormalities or fetal or 
neonatal renal failure. 
Although the above reports give supportive 
evidence for the safety of ACE inhibitors in early 
pregnancy, further clinical experience is warranted 
for risk assessment. 
Cooper et al. conducted a study to assess 
the association between exposure to ACE 
inhibitors during the first trimester of pregnancy 
and risk of congenital malformations. They 
followed 29.507 infants from Tennessee Medicaid 
files who were born between 1985 and 2000 and 
whose mothers had no evidence of diabetes. It 
was identified that, from all those babies, 209 
babies were exposed to ACE inhibitors during the 
first trimester only, 202 were exposed to other 
antihypertensives during the first trimester only, and 
29. 096 babies were not exposed to antihypertensive 
drugs. The risk of major congenital malformations 
was higher in infants who had been exposed to 
ACE inhibitors, compared with infants who had 
not been exposed to antihypertensives, while 
exposition to other antihypertensive medications 
did not increase the risk of major malformations. 
ACE inhibitors increased risk of malformations of 
the cardiovascular system and the central nervous 
system. The authors concluded that exposure to 
ACE inhibitors during the first trimester of 
pregnancy should be avoided because they 
cannot be considered safe (71). 
Also, it has been suggested that this agents 
should be avoided by women who attempt to 
conceive (72). 
Based upon the analyzed association between 
a child born with renal impairment following 
anhydramnios and maternal exposure to an 
angiotensin II receptor type 1 (AT1) antagonist, 
valsartan, and hydrochlorothiazide during the 
first 28 weeks of pregnancy, Bos-Thompson et al. 
concluded that AT1 antagonists should be 
avoided throughout pregnancy because they 
reduce fetal kidney perfusion that may result in 
oligoamnios and neonatal renal insufficiency (73). 
 
Conclusion 
 
All hypertensive disorders of pregnancy are 
associated with increased maternal and perinatal 
risks, but the relation between benefits and risks 
of using any antihypertensive agent in pregnancy 
have not been still completely defined. There is 
consensus that women with severe hypertension 
should receive antihypertensive treatment in 
order to decrease the risk of stroke eclampsia or 
death, but in cases of mild-to-moderate 
hypertension, the attitudes of antihypertensive 
therapy usage are still controversial.  
From a wide palette of antihypertensives, 
the most acceptable agents are methyldopa, 
labetalol, and nifedipine, in standard doses. The 
usage of atenolol should be avoided in 
pregnancy, because it has been associated with 
lower birth weights and fetal growth impairment. 
ACE inhibitors and angiotensin receptor blockers 
are contraindicated in pregnancy and they should 
be avoided in all trimesters of pregnancy. In control 
of severe hypertension, intravenous labetalol or 
oral nifedipine is as effective as intravenous 
hydralazine, with less adverse effects. 
Although there are many antihypertensive 
agents, large randomized controlled studies are 
needed to establish BP levels for the beginning of 
drug treatment, define specific drugs, and finally, 
to solve whether antihypertensive therapy in 
mild-to-moderate hypertension in pregnancy have 
greater benefits than risks for mother and fetus. 
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ANTIHIPERTENZIVNA TERAPIJA KOD HIPERTENZIVNIH 
POREMEĆAJA U TRUDNOĆI 
 
Marko Folić, Nevena Folić, Mirjana Varjačić, Mihajlo Jakovljević i Slobodan Janković 
 
 
Hipertenzija u trudnoći je udružena sa povišenim stepenom morbiditeta i mortaliteta 
majke i ploda. Oko 8% od ukupnog broja trudnoća komplikuje se hipertenzivnim 
poremećajima. Postoji opšta saglasnost o neophodnosti što hitnijeg lečenja budućih majki 
sa teškom hipertenzijom u cilju smanjenja rizika razvoja akutnih cerebrovaskularnih 
komplikacija. U kontroli teških oblika hipertenzije, intravenozno aplikovan labetalol ili 
oralno dat nifedipin su podjednako efikasni ali i udruženi sa manjim brojem neželjenih 
reakcija u odnosu na intravenozno ordiniran hidralazin. Opšteg stava u vezi sa potrebom 
lečenja blage do umerene hipertenzije u trudnoći još uvek nema, s obzirom da definitivni 
zaključci po pitanju odnosa potencijalnih koristi/rizika uzrokovanih primenom 
antihipertenzivne terapije u trudnoći još uvek ne postoje. S obzirom na bezbednu primenu 
u trudnoći, metildopa, labetalol i nifedipin su često korišćeni lekovi za regulaciju krvnog 
pritiska kod trudnica sa hipertenzijom. Kardioselektivni β blokator atenolol treba izbegavati 
u trudnoći jer dovodi do sniženja telesne težine na rođenju i smanjenja fetalnog rasta. 
Upotreba ACE inhibitora i blokatora angiotenzinskih receptora je kontraindikovana u 
trudnoći. Acta Medica Medianae 2008;47(3):65-72. 
 
Ključne reči: antihipertenzivni lekovi, hipertenzivni poremećaji, trudnoća 
 
 